/
MNPR
$94.56+$6.88 (+7.85%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$587.4M
7M shares
52-week range
$29.18 – $105.00
86% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.86%
Moderate
Price (6 mo)
Loading chart…
Change+$65.31
Monopar Therapeutics Inc. Common Stock
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
www.monopartx.com- Employees
- 22
- IPO / List date
- Dec 19, 2019
- HQ
- WILMETTE, IL
Held by traders on TradeandTell
No one on the platform currently holds MNPR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 11,431 | $746.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-13 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded MNPR yet.
